USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Ivax Pharmaceuticals Ireland

USPTO PatentsView assignee record - 22 granted patents across 6 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

RSS updates for this company

The verdict

According to USPTO PatentsView, Ivax ranks #13,504 of 49,997 tracked US assignees by granted-patent volume, with 22 patents across 6 technology areas.

#13,504
of 49,997 US assignees by volume
30th percentile
by Innovation Score (29.1/100)
13.3
avg claims per patent
-84%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13504 · Foreign Corporation #13,504 · 22 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-SMALL 22 grants
  • MID-PACK #13,504/49,997
  • PHOTO-FINISH Invatec S P A
  • CPC-NARROW A61M · 6 areas
  • INNOV-THIN 29.1/100
  • CLAIMS-RICH 13.3 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -84% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Invatec S.P.A (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Ivax

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Ivax's Innovation Score is 29.1/100 (30th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Ivax's grants concentrate

Ivax Pharmaceuticals Ireland is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2015 (5 grants) versus a trough of 1 in 2022. By volume, Ivax sits between Invatec S.P.A and Japan Display West Inc..

Ivax's three-year grant acceleration

Ivax Pharmaceuticals Ireland shows 1 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Ivax's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Ivax holds 22 patents at rank #13,502, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Ivax

By rank, the assignees closest to #13,502 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Ivax's primary technology class.

Ivax's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 30th percentile higher than 30% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0123456 2015201620172018201920202022 1
USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Ivax Pharmaceuticals Ireland patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 5 22.7%
2016 3 13.6%
2017 4 18.2%
2018 5 22.7%
2019 2 9.1%
2020 2 9.1%
2022 1 4.5%

Where it ranks

Overall rank by patents

#13,504

of 49,997 tracked assignees

Innovation Score

29.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Ivax Pharmaceuticals Ireland's patent record in context - here's where to go next.

  • Ivax Pharmaceuticals Ireland's lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 100% of its portfolio - see every assignee active in that class. Explore A61M
  • Ranked #13,504 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Ivax Pharmaceuticals Ireland against Invatec S.P.A, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 29.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.